

Musculoskeletal Australia



MUSCULOSKELETAL
AUSTRALIA

Consumer input to the Pharmaceutical Benefits Advisory Committee (PBAC)

Musculoskeletal relevant drugs for consideration at the March 2023 PBAC Meeting

Below is a list of the musculoskeletal relevant drugs for consideration by the PBAC at their next meeting in March 2023. Consumer comments about any of these drugs must be received by the PBAC **by 5pm (AEST) on Wednesday 25 January 2023**.

If you wish to submit your comments to PBAC with the help of the MSK staff, please respond to the questions in the last column of the table below via email **by no later than 5pm (AEST) on Wednesday, 18 January 2023**. Please send your email responses to programs@msk.org.au

Drug name	Musculoskeletal condition/s (What is the drug used to treat?)	Purpose of the submission (Nature of the request by the sponsor or drug company)	If you wish to make a comment about these requests via MSK, please respond to the following questions
ANIFROLUMAB Solution concentrate for I.V. infusion 300 mg in 2 mL vial Saphnelo® AstraZeneca Pty Ltd (New PBS listing)	Systemic lupus erythematosus (SLE)	AstraZeneca Pty Ltd is putting in a resubmission requesting a Section 100 (Highly Specialised Drugs Program) Authority Required (written) listing for the treatment of severe SLE with a high degree of disease activity despite standard therapy. The drug brand name is Saphnelo®	1) How does having the listed condition affect your daily life? 2) What are the reasons why your current treatment isn't fully meeting your needs? 3) What do you think would be the benefits (or additional benefits) of having this drug available? 4) Are there any reasons why you think this request should not be approved?

Drug name	Musculoskeletal condition/s (What is the drug used to treat?)	Purpose of the submission (Nature of the request by the sponsor or drug company)	If you wish to make a comment about these requests via MSK, please respond to the following questions
<p style="text-align: center;">APREMILAST</p> <p>Tablet 30 mg Pack containing 4 tablets of 10 mg, 4 tablets of 20 mg and 19 tablets of 30 mg</p> <p style="text-align: center;">Otezla®</p> <p>Amgen Australia Pty Limited (Change to PBS listing)</p>	<p style="text-align: center;">Psoriatic arthritis (PsA)</p>	<p>Amgen Australia is requesting a General schedule Authority Required (STREAMLINED) listing for the treatment of severe active PsA. The drug brand name is Otezla®</p>	<p>1) How does having the listed condition affect your daily life? 2) What are the reasons why your current treatment isn't fully meeting your needs? 3) What do you think would be the benefits (or additional benefits) of having these tablets available? 4) Are there any reasons why you think this request should not be approved?</p>
<p style="text-align: center;">ROMOSOZUMAB</p> <p>Injection 105 mg in 1.17 mL single use pre filled syringe</p> <p style="text-align: center;">Evenity®</p> <p>Amgen Australia Pty Limited (Change to PBS listing)</p>	<p style="text-align: center;">Osteoporosis</p>	<p>Amgen Australia is resubmitting a request for a General Schedule Authority Required (Telephone/electronic) listing for the treatment of severe established osteoporosis. The drug brand name is Evenity®</p>	<p>1) How does having this condition affect your daily life? 2) What are the reasons why your current treatment isn't fully meeting your needs? 3) What do you think would be the benefits (or additional benefits) of having this drug available? 4) Are there any reasons why you think this request should not be approved?</p>

Drug name	Musculoskeletal condition/s (What is the drug used to treat?)	Purpose of the submission (Nature of the request by the sponsor or drug company)	If you wish to make a comment about these requests via MSK, please respond to the following questions
<p>TOFACITINIB</p> <p>Tablet 5 mg</p> <p>Xeljanz®</p> <p>Pfizer Australia Pty Ltd (Change to PBS listing)</p>	<p>Ankylosing spondylitis</p>	<p>Pfizer Australia is requesting a General Schedule Authority Required (written) listing for the treatment of ankylosing spondylitis. The drug brand name is Xeljanz®.</p>	<p>1) How does having this condition affect your daily life?</p> <p>2) What are the reasons why your current treatment isn't fully meeting your needs?</p> <p>3) What do you think would be the benefits (or additional benefits) of having this drug available?</p> <p>4) Are there any reasons why you think this request should not be approved?</p>
<p>TOFACITINIB</p> <p>Tablet 5 mg Oral liquid 1 mg per mL, 240 mL</p> <p>Xeljanz®</p> <p>Pfizer Australia Pty Ltd (New PBS listing)</p>	<p>Juvenile idiopathic arthritis (JIA)</p>	<p>Pfizer Australia is requesting a General Schedule Authority Required (written) listing for the treatment of severe active juvenile idiopathic arthritis. The drug brand name is Xeljanz®.</p>	<p>1) How does you or your child having JIA affect your/their daily life?</p> <p>2) What are the reasons why your/their current treatment isn't fully meeting your/their needs?</p> <p>3) What do you think would be the benefits (or additional benefits) of having this drug available?</p> <p>4) Are there any reasons why you think this request should not be approved?</p>